4//SEC Filing
Gupta Shalabh K. 4
Accession 0001213900-23-056848
CIK 0001766140other
Filed
Jul 12, 8:00 PM ET
Accepted
Jul 13, 6:10 PM ET
Size
15.2 KB
Accession
0001213900-23-056848
Insider Transaction Report
Form 4
Gupta Shalabh K.
DirectorCEO
Transactions
- Exercise/Conversion
Warrant (right to buy)
2023-07-11+72,047→ 72,047 totalExercise: $0.59From: 2023-07-11→ Series A-4 Convertible Preferred Stock (72,047 underlying) - Exercise/Conversion
Common Stock
2023-07-11+104,612→ 2,527,449 total - Exercise/Conversion
Warrant (right to buy
2023-07-11+79,252→ 79,252 totalExercise: $0.54From: 2023-07-11→ Series A-3 Convertible Preferred Stock (79,252 underlying) - Exercise/Conversion
Warrant (right to buy)
2023-07-11+115,275→ 115,275 totalExercise: $0.74From: 2023-07-11→ Series A-5 Convertible Preferred Stock (115,275 underlying) - Exercise/Conversion
Series A-1 Convertible Preferred Stock
2023-07-11$1000.00/sh−50$50,000→ 0 totalExercise: $0.49→ Common Stock
Footnotes (5)
- [F1]The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.
- [F2]On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion.
- [F3]The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb.
- [F4]The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb.
- [F5]The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment.
Documents
Issuer
Unicycive Therapeutics, Inc.
CIK 0001766140
Entity typeother
Related Parties
1- filerCIK 0001864917
Filing Metadata
- Form type
- 4
- Filed
- Jul 12, 8:00 PM ET
- Accepted
- Jul 13, 6:10 PM ET
- Size
- 15.2 KB